Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Adalimumab/adverse effects"'
Autor:
Hendrik Otto, Grazyna Pulka, Külli Kingo, Roshan Dias, Fausto Berti, Richard Kay, Halimu N. Haliduola, Nataliya Reznichenko, Eric Guenzi, George Galdava, Steven R. Feldman, Joanna Sobierska, Heimo Stroissnig
Publikováno v:
Feldman, S R, Reznichenko, N, Pulka, G, Kingo, K, George Galdava, Berti, F, Sobierska, J, Dias, R, Guenzi, E, Hendrik Otto, Haliduola, H N, Kay, R & Stroissnig, H 2021, ' Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis : A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study ', BioDrugs, vol. 35, no. 6, pp. 735-748 . https://doi.org/10.1007/s40259-021-00502-w
Biodrugs
Biodrugs
Background AVT02 (adalimumab) is a proposed biosimilar to Humira®. AVT02 is produced at a 100 mg/mL concentration with a citrate-free formulation. Objectives The aim of this study was to compare the efficacy, safety and immunogenicity of AVT02 versu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9abf66f1bee2ff164778cbe7acdd210a
https://findresearcher.sdu.dk:8443/ws/files/195534959/Feldman2021_Article_EfficacySafetyAndImmunogenicit.pdf
https://findresearcher.sdu.dk:8443/ws/files/195534959/Feldman2021_Article_EfficacySafetyAndImmunogenicit.pdf
Autor:
Alexander A. Navarini, Curdin Conrad, Alessio Mylonas, Anne-Karine Lapointe, Jeremy Di Domizio, Olivier Demaria, Michel Gilliet, Cyrine Belkhodja, Lars E. French, Maxime Vernez
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Nature Communications
Nature communications, vol. 9, no. 1, pp. 25
Nature Communications
Nature communications, vol. 9, no. 1, pp. 25
Although anti-tumor necrosis factor (TNF) agents are highly effective in the treatment of psoriasis, 2–5% of treated patients develop psoriasis-like skin lesions called paradoxical psoriasis. The pathogenesis of this side effect and its distinction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbbc7decb248c10970a313c075620f0f
https://doaj.org/article/180fc992d72e4fcbbf1d606055e86015
https://doaj.org/article/180fc992d72e4fcbbf1d606055e86015
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Patricia Zacharias, Álvaro Steckert Filho, Diogo Araujo Ribeiro, Larissa Boaron, Mariella Bau, Paulo Gustavo Kotze
Publikováno v:
Arquivos de Gastroenterologia, Iss 0 (2017)
Arquivos de Gastroenterologia v.54 n.4 2017
Arquivos de gastroenterologia
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
instacron:IBEPEGE
Arquivos de Gastroenterologia, Volume: 54, Issue: 4, Pages: 328-332, Published: 21 SEP 2017
Arquivos de Gastroenterologia v.54 n.4 2017
Arquivos de gastroenterologia
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
instacron:IBEPEGE
Arquivos de Gastroenterologia, Volume: 54, Issue: 4, Pages: 328-332, Published: 21 SEP 2017
BACKGROUND: Infliximab and adalimumab are considered effective drugs in the management of Crohn’s disease. However, due to significant immunossupression, they can cause important adverse events, mostly infections. OBJECTIVE: The aim of this study w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d493b8feeef4f7d9b4bbcb6d45f61a1
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032017005009105&lng=en&tlng=en
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032017005009105&lng=en&tlng=en